Cencora Beats on Q4 Adjusted EPS of $4.66, Guides FY27 to $19.40-$19.75 and Raises Dividend 10%
COR sits 40% above its 52-week low of $244.82.
Summary
Cencora beat fourth-quarter adjusted EPS estimates at $4.66 and guided fiscal 2027 adjusted EPS to $19.40-$19.75, while raising its dividend 10% and reorganizing into two new reporting segments.
Key Events · Earnings and Guidance · COR
-
Q4 Adjusted EPS Beats Consensus
Adjusted diluted EPS of $4.66 rose 21.4% year over year and topped the $4.58 IBES estimate; revenue grew 5.5% to $88.4 billion.
-
FY27 Guidance Set at $19.40-$19.75
The midpoint of $19.58 implies about 9% growth over fiscal 2026 adjusted EPS of $17.97; adjusted operating income is guided to 4%-6% growth off $4.8 billion.
-
Dividend Raised 10%
The quarterly dividend increased to $0.66 per share from $0.60, payable November 30, 2026 to holders of record November 13, 2026.
-
New Segment Structure From Q1 FY27
Reporting moves to Pharmaceutical Distribution and Services ($284.5B FY26 revenue base) and Specialty Pharmaceutical and Provider Services ($45.4B), with long-term operating income growth targets of mid-single digit and mid-teens respectively.
Analysis · COR · Trade & Services
Cencora closed fiscal 2026 with fourth-quarter adjusted EPS of $4.66, ahead of the $4.58 consensus, on revenue of $88.4 billion. For holders, the forward-looking news matters more: management set fiscal 2027 adjusted EPS guidance of $19.40 to $19.75, which at the midpoint implies roughly 9% growth off the $17.97 just delivered, and lifted the quarterly dividend 10% to $0.66. The company also reorganized into two new reporting segments — Pharmaceutical Distribution and Services, and Specialty Pharmaceutical and Provider Services — and gave long-term operating income growth targets for each, with specialty targeted at mid-teens growth. That reframes the equity story around the higher-margin specialty and provider-services business built through OneOncology rather than the low-margin wholesale core. Offsetting the good print: net interest expense rose 75% to $136.3 million as debt funded the OneOncology deal, and fiscal 2027 free cash flow is guided to about $3.5 billion versus $3.8 billion in fiscal 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COR was trading at $342.67 on NYSE in the Trade & Services sector, with a market capitalization of approximately $65B. The 52-week trading range was $244.82 to $377.54. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.